CSG Juggles KNDS Ambition and Ukraine Coalition Setback as Stock Languishes

The Czechoslovak Group has kicked off the trading week with a blockbuster M&A proposition that could reshape Europe's defence landscape – but the political hurdles are steep, and a separate blow to its Ukraine munitions pipeline is adding to investor unease. The Czech defence conglomerate is reported to have tabled a predominantly cash offer to the Bode-Wegmann family for a significant stake in KNDS, the Franco-German armoured vehicle and artillery giant. The family holds half of KNDS; the French state owns the remainder. For CSG, such a deal would be the most ambitious in its corporate history, placing it at the heart of Europe's rearmament push.

Yet the path is narrow. German family shareholders are understood to favour an initial public offering combined with a partial sale to the German government, which is examining a 30% to 40% stake before any listing. KNDS itself is working toward a flotation by early July, targeting a valuation of €15 billion to €20 billion. Neither side has commented publicly, and the offer remains unconfirmed.

Complicating the narrative, a key funding coalition behind CSG's role in supplying artillery shells to Ukraine is shrinking. According to a Defence Industry Europe report from 28 May, only nine of the original 18 participant states remain in the Czech-led initiative. CSG acts as the main contractor, purchasing shells from non-NATO sources for Kyiv's Western backers. The programme has delivered over 4 million rounds – roughly half of all allied ammunition shipments to Ukraine – but a narrower funding base could slow future procurement. Germany and several Nordic countries are still on board, but the exodus of half the partners raises questions about the pace of new orders.

At the bourse, CSG shares ended last Friday at €18.06, virtually flat on the day but down 3.41% for the week. The stock has been volatile: a 6.3% plunge on Wednesday was followed by a 3.6% rebound on Thursday. Technically, the picture remains shaky. The price sits 13.41% below its 50-day moving average, while annualised 30-day volatility stands at a lofty 77.2%. The relative strength index of 60.9 points to neutral territory, but the gap to the January high – some 46.59% lower – underscores the broader bearish pressure.

Should investors sell immediately? Or is it worth buying CSG?

That pressure has been amplified by accusations from short-seller Hunterbrook, which alleged that CSG failed to adequately disclose information in its IPO prospectus regarding subsidiaries and business practices. CSG has dismissed the claims. Analysts, however, remain broadly positive. The average 12-month price target is €32.45, with a range of €25 to €42, and all ten covering analysts rate the stock a buy.

The first-quarter numbers since listing provide some counterweight to the negativity. Revenue rose 13.8% to €1.544 billion, powered by a 26.5% jump in the Defence Systems segment. Operating EBIT reached €372 million, translating into a 24.1% margin that sits comfortably within the company's full-year target range. Management reaffirmed its revenue outlook of €7.4 billion to €7.6 billion. Credit rating agencies have also thrown their weight behind the group: Moody's lifted CSG to Baa3, investment grade, while Fitch affirmed BBB-.

The order book stands at €17 billion, with an additional pipeline of €27 billion. That gives the company considerable visibility, but the market is watching whether the thinning Ukraine coalition will crimp future order intake. A close above the five-day average of €18.24 would signal that investors have digested the news; a break below the weekly low of €17.40 would suggest deepening scepticism. The half-year results, due in August, will be the next major test of momentum.

CSG at a turning point? This analysis reveals what investors need to know now.

Beyond the KNDS bid and the Ukraine programme, CSG has other catalysts in play. Its subsidiary ZVS Holding signed a framework agreement with the Slovak defence ministry for ammunition that could be worth up to €58 billion, potentially financed through the EU's SAFE programme offering 1% loans over 40 years. The catch: Slovakia needs at least one more EU partner, Romania has already declined, and Croatia remains uncommitted. The country-specific exemption expires at the end of May 2026. Separately, the acquisition of a 49% stake in Austria's Hirtenberger Defence Systems is awaiting regulatory approval, which would strengthen CSG's mortars and ammunition capabilities.

The macro tailwind remains strong. Global military spending hit roughly $2.887 trillion in 2025, with European outlays rising 14% the same year, and NATO members have committed to allocating 5% of GDP to defence and defence-related spending annually by 2035. CSG aims to boost production of large-calibre ammunition to around 850,000 rounds by the end of 2026, up from 550,000 last year. For the week ahead, three specific triggers stand out: any movement on the KNDS offer, the SAFE deadline, and potential news on the Hirtenberger clearance. Investors will be watching closely to see whether the company's strategic ambition can overcome the political friction.

Ad

CSG Stock: New Analysis - 31 May

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...

en | NL0015073TS8 | CSG | boerse | 69451828 |